Shames Daniel 4
4 · Mereo BioPharma Group plc · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Mereo BioPharma (MREO) Director Daniel Shames Receives Award
What Happened
Daniel Shames, a director of Mereo BioPharma Group plc (MREO), received two derivative equity awards on February 26, 2026 totaling 162,163 units (66,000 and 96,163). One award is reported at $0.00 per share (no cash paid); the other lists price as N/A. These are grants (A) — deferred restricted stock units (DRSUs) rather than open-market purchases or sales.
Key Details
- Transaction date: 2026-02-26; filing date: 2026-02-27 (timely).
- Awards: 66,000 and 96,163 derivative units; combined total 162,163 units. Reported acquisition prices: $0.00 and N/A.
- Shares owned after transaction: Not specified in the filing.
- Footnotes:
- F1: Awards vest in substantially equal monthly installments over one year from the grant date.
- F2: Each American Depositary Share (ADS) represents five ordinary shares (GBP 0.003 par value).
- F3: These are DRSUs granted to non‑executive directors who elected to receive DRSUs in ADS form; DRSUs vest monthly over the plan year and are generally paid in ADSs 180 days after separation of service.
- Transaction code: A = Award/Grant (derivative). No 10b5-1 or tax-withholding mechanics specified.
Context
DRSUs are deferred compensation and do not represent immediately tradable ordinary shares until vested and settled (here, often in ADSs). Such director awards are a routine form of compensation and are informational rather than a direct buy/sell signal.
Insider Transaction Report
- Award
Share Options (Right to buy)
[F1][F2]2026-02-26+66,000→ 66,000 totalExercise: $0.39Exp: 2036-02-26→ American Depositary Shares (66,000 underlying) - Award
Deferred Restricted Stock Units
[F3][F2]2026-02-26+96,163→ 96,163 total→ American Depository Shares (96,163 underlying)
Footnotes (3)
- [F1]Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
- [F2]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
- [F3]Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.